Analyst Reco. Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse Other stock markets 04:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
8.08 ^USD	+1.13%		+0.87%	+59.06%

May. 20	Transcript : Actinium Pharmaceuticals, Inc. - Special Call
May. 15	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target	May. 14	MT
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating	Mar. 19	MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating	Dec. 11	MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60	23-09-06	MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating	23-08-15	MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating	23-03-02	MT
William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform	23-02-21	MT
HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating	22-10-31	MT
B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating	22-10-31	MT
Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target	22-09-08	MT
B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated	22-08-25	MT
Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating	22-04-13	MT
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML	21-12-14	CI
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating	21-08-03	MT
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating	21-04-01	MT
Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH	20-12-08	CI
ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target	20-11-05	MT
Actinium Pharmaceuticals : Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10%	20-11-04	MT
Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML	20-11-04	CI
Actinium Pharmaceuticals, Inc. Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting	19-12-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Analyst Reco.

Filters